Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva

Cephalon product sales boost results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva

1Q Revenues: $5.1 billion (+25%)

1Q Earnings: $855.0 million (+12%)

Comments: Revenues in the U.S. were +46% to $2.8 billion, primarily due to the inclusion of Cephalon product sales. Revenues in Europe were $1.3 billion (-2%), impacted by ongoing macro-economic conditions and healthcare reforms in key European markets. Rest of the World sales totaled +21% to $1 billion, driven by the inclusion of Taiyo and Cephalon. Generic revenues were $2.6 billion (including API revenues of $199 million), up 12%. The U.S. generics business benefited from the launch of seven products, as well as its Ranbaxy agreement relating to its launch of generic Lipitor. The European generics business declined due to continued economic and regulatory pressures. Branded products revenues were $2.1 billion, up 54%, primarily due to the inclusion of Cephalon sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters